Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00383149 · ClinicalTrials.gov registry record · Phase 2

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

A Phase 2 study of Metastatic Pancreatic Cancer, sponsored by R-Pharm.

Completed
Registry status
Phase 2
Development phase
58
Enrollment target
9
Study locations

NCT00383149 is a Phase 2 study of Metastatic Pancreatic Cancer that has completed, run by R-Pharm. The registered enrollment target is 58 participants, below the 105-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (45% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00383149, a Phase 2 study of Metastatic Pancreatic Cancer, has completed, sponsored by R-Pharm.

COMPLETED
Registry status
Phase 2
Development phase
58 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.

Conditions Studied

Metastatic Pancreatic Cancer

Interventions

  • DRUG Cetuximab
  • DRUG Ixabepilone

Study Locations (9)

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • University Of Miami - Miami

Michigan

  • University Of Michigan - Ann Arbor
  • Wayne State University - Detroit

District of Columbia

  • Georgetn Univ Lombardi Can Ctr - Washington D.C.

Missouri

  • Ellis Fischel Cancer Center - Columbia

South Carolina

  • Cancer Centers Of The Carolinas - Greenville

Washington

  • Seattle Cancer Care Alliance - Seattle

West Virginia

  • West Virginia University - Morgantown

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2007-01
Est. Completion 2009-06
Phase Phase 2

Sponsor

R-Pharm

19 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00383149

The ClinicalTrials.gov registry entry for NCT00383149 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (45% lower). The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.

NCT00383149 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, Michigan, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00383149 about?

NCT00383149 is a clinical study titled "A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer". The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.

What is the current status of trial NCT00383149?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2007-01. Estimated completion is 2009-06.

What conditions does trial NCT00383149 study?

This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.

What interventions are being tested in trial NCT00383149?

The interventions under investigation include: Cetuximab (DRUG), Ixabepilone (DRUG).

Who is sponsoring clinical trial NCT00383149?

This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00383149 being conducted?

This trial has 9 study locations across District of Columbia, Florida, Michigan, Missouri, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Pancreatic Cancer

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.